搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
ENDPOINTS NEWS
6 小时
Drug inspector attrition leads to 'many fewer' checks than 2016 peak, GAO says
The GAO report highlights FDA's drug inspection program challenges, including 36% fewer inspections in 2023 compared to 2019 ...
ENDPOINTS NEWS
8 小时
Danish biotech Gubra touts early weight loss data in hot amylin field
The amylin field is heating up ahead of Novo Nordisk's much-anticipated CagriSema readout later this year. On Wednesday, ...
ENDPOINTS NEWS
11 小时
J&J takes 340B fight with federal government to court
Johnson & Johnson is suing the federal government over HRSA's rejection of its proposed 340B drug discount model for Xarelto ...
ENDPOINTS NEWS
11 小时
Adaptimmune's second T cell receptor cell therapy for rare sarcomas ...
Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in ...
ENDPOINTS NEWS
12 小时
Primary care unicorn startup Forward Health shuts down
Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...
ENDPOINTS NEWS
13 小时
Metsera raises $215M for studies of GLP-1 and amylin obesity drugs
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
ENDPOINTS NEWS
13 小时
Otsuka and ICU Medical forge IV manufacturing network to supply the US
Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...
ENDPOINTS NEWS
15 小时
Exclusive: Flagship names two CEO-partners to lead Valo Health, Apriori Bio
Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its spinouts Apriori ...
ENDPOINTS NEWS
15 小时
TRexBio raises $84M to take in-house immune program into the clinic
TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...
ENDPOINTS NEWS
15 小时
After stock slides, Amgen addresses bone density talk on obesity drug
A lot of Amgen's future rides on its experimental obesity medicine MariTide. At least in the minds of investors. Ahead of the ...
ENDPOINTS NEWS
15 小时
New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug
BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...
ENDPOINTS NEWS
16 小时
Syros' shares plummet as blood cancer drug fails again
Syros Pharmaceuticals’ share price nosedived after its last drug candidate flunked a trial in hematological ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈